Cancers, Free Full-Text
Por um escritor misterioso
Descrição
As lung cancer has the highest cancer-specific mortality rates worldwide, there is an urgent need for new therapeutic and diagnostic approaches to detect early-stage tumors and to monitor their response to the therapy. In addition to the well-established tissue biopsy analysis, liquid-biopsy-based assays may evolve as an important diagnostic tool. The analysis of circulating tumor DNA (ctDNA) is the most established method, followed by other methods such as the analysis of circulating tumor cells (CTCs), microRNAs (miRNAs), and extracellular vesicles (EVs). Both PCR- and NGS-based assays are used for the mutational assessment of lung cancer, including the most frequent driver mutations. However, ctDNA analysis might also play a role in monitoring the efficacy of immunotherapy and its recent accomplishments in the landscape of state-of-the-art lung cancer therapy. Despite the promising aspects of liquid-biopsy-based assays, there are some limitations regarding their sensitivity (risk of false-negative results) and specificity (interpretation of false-positive results). Hence, further studies are needed to evaluate the usefulness of liquid biopsies for lung cancer. Liquid-biopsy-based assays might be integrated into the diagnostic guidelines for lung cancer as a tool to complement conventional tissue sampling.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Cancers, Free Full-Text
Cancers, Free Full-Text
Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study - The Lancet Digital Health
Know the signs of cancer to catch it early
Hallmarks of Cancer: The Next Generation: Cell
Illusion Registry Fixer 1.4 Download - Colaboratory
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
/i.s3.glbimg.com/v1/AUTH_08fbf48bc0524877943fe86e43087e7a/internal_photos/bs/2021/V/6/E7wnUwTOeBWt63X1KcVg/2013-09-05-pokemon-x-y-mega-evolucao-venusaur-mega-venusaur.png)
